Harnessing dendritic cells for pancreatic cancer immunotherapy: a novel promising approach

Hui Zeng; Yidong Wu; Xinghua Long

doi:10.1002/mco2.70066

MedComm ›› 2025, Vol. 6 ›› Issue (1) : e70066 DOI: 10.1002/mco2.70066

HIGHLIGHT

Harnessing dendritic cells for pancreatic cancer immunotherapy: a novel promising approach

Hui Zeng ¹^,²
, Yidong Wu ²
, Xinghua Long ¹^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Hui Zeng, Yidong Wu, Xinghua Long. Harnessing dendritic cells for pancreatic cancer immunotherapy: a novel promising approach. MedComm, 2025, 6(1): e70066 DOI:10.1002/mco2.70066

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Mahadevan KK, Dyevoich AM, Chen Y, et al. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Science. 2024; 384(6703): eadh4567.

[2]	Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. 2019; 156(7): 2056-2072.

[3]	Bear AS, Vonderheide RH, O’Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. 2020; 38(6): 788-802.

[4]	De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003; 63(1): 12-17.

[5]	Garris CS, Arlauckas SP, Kohler RH, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12. Immunity. 2022; 55(9): 1749.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.